ePT--the Electronic Newsletter of Pharmaceutical Technology, Mar 3, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Mar 3, 2011
News
FDA Removes from Market Unapproved Cough and Cold Prescription Products
By Angie Drakulich
FDA announced on Mar. 2, 2011, that it is taking action against companies that manufacture, distribute, or market certain unapproved prescription oral cough, cold, and allergy products, according to an agency release.
FDA Sends sanofi aventis Two Warning Letters
By Erik Greb
FDA recently sent sanofi-aventis two Warning Letters for its facilities in Frankfurt am Main, Germany, and Bridgewater, NJ.
Merck Sells Contract Biopharmaceutical Business to Fujifilm
By Patricia Van Arnum
Fujifilm and Merck & Co. have formed a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a contract biopharmaceutical manufacturing and development business of Merck.
EU–India FTA Dispute Continues
By Stephanie Sutton
Ongoing Free Trade Agreement (FTA) negotiations between the EU and India have hit a hurdle as some stakeholders urge the Indian government to fight against certain provisions in the FTA amid fears that access to generic drugs may be affected.
EMA Challenged Over Conflict-of-Interest Case
By Stephanie Sutton
A number of European public health and transparency campaigners believe that conflict of interest rules may have been breached with the EMA's decision to allow its former Executive Director, Thomas Lönngren, to take up an advisory role within the private pharmaceutical sector.
Rare Disease Day 2011 – "Rare but Equal"
By Rich Whitworth
The European Organization for Rare Diseases (EURORDIS), an alliance of patient organizations and individuals, celebrated its fourth Rare Disease Day on February 28.
Week of Feb. 28, 2011: Company and People Notes: Pfizer Completes King Acquisition; ViiV Healthcare Names Chairman; and More.
Pfizer Completes King Acquisition; ViiV Healthcare Names Chairman; and More.
Regulatory Roundup: FDA and Georgetown University Form Innovation Partnership
FDA and Georgetown University Form Innovation Partnership

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here